Cracking The Code: Understanding Analyst Reviews For Intellia Therapeutics

In the last three months, 4 analysts have published ratings on Intellia Therapeutics NTLA, offering a diverse range of perspectives from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Intellia Therapeutics, presenting an average target of $48.25, a high estimate of $70.00, and a low estimate of $29.00. A decline of 8.39% from the prior average price target is evident in the current average.

Understanding Analyst Ratings: A Comprehensive Breakdown

A comprehensive examination of how financial experts perceive Intellia Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Intellia Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Intellia Therapeutics compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Intellia Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Intellia Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Intellia Therapeutics analyst ratings.

Get to Know Intellia Therapeutics Better

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics's Economic Impact: An Analysis

Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.

Revenue Growth: Over the 3 months period, Intellia Therapeutics showcased positive performance, achieving a revenue growth rate of 129.53% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -371.3%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Intellia Therapeutics's ROE excels beyond industry benchmarks, reaching -10.3%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Intellia Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.39%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Intellia Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.

How Are Analyst Ratings Determined?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.